About Apnimed
Apnimed is a company based in Cambridge (United States) founded in 2017 by Lawrence G Miller. Apnimed has raised $249.33 million across 9 funding rounds from investors including NexPoint, Alpha Wave Global and Sectoral Asset Management. Apnimed offers products and services including AD109. Apnimed operates in a competitive market with competitors including Aculys, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others.
- Headquarter Cambridge, United States
- Founders Lawrence G Miller
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apnimed Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$249.33 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Debt – Conventional
Apr 07, 2026
-
Investors
NexPoint
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Apnimed
Apnimed offers a comprehensive portfolio of products and services, including AD109.
Investigational treatment for improving oxygenation in obstructive sleep apnea.
People of Apnimed
Unlock access to complete
Funding Insights of Apnimed
Apnimed has successfully raised a total of $249.33M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Apnimed
Apnimed has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NexPoint, Alpha Wave Global and Sectoral Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on growth-stage companies
|
Locked | Locked | Locked | |
|
Sectoral Asset Management is focused on global healthcare investment.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Apnimed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apnimed
Investment portfolio details for Apnimed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Apnimed
Detailed financials for Apnimed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apnimed Comparisons
Peer comparison for Apnimed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Apnimed
Apnimed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aculys, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic medicines for neuropsychiatric and sleep disorders are developed.
|
|
| Locked | Locked | Locked |
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for sleep apnea are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat circadian rhythm disruption
|
|
| Locked | Locked | Locked |
Provider of natural remedy based mental & physical wellbeing services
|
Detailed competitors of Apnimed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apnimed
Complete news archive for Apnimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apnimed
Apnimed was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Apnimed is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Lawrence G Miller is the current CEO of Apnimed. They have also founded this company.
Apnimed is a funded company, having raised a total of $249.33M across 9 funding rounds to date.
Apnimed was founded in 2017 and is based in Cambridge, United States. Small molecule-based therapeutics are developed by the company within the biotechnology sector for treating obstructive sleep apnea. A combination therapy of atomoxetine and oxybutynin has been formulated to lessen the conditions severity. Neurological mechanisms controlling upper airway dilator muscles are addressed, resulting in enhanced respiration and oxygenation while sleeping. Operations focus on advancing these treatments through clinical development.
Apnimed's top competitors include Mosanna Therapeutics, Avadel Pharmaceuticals and Aculys.
Apnimed offers AD109.
Apnimed has 7 investors. Key investors include NexPoint, Alpha Wave Global, Sectoral Asset Management, Tao Capital Partners, and Columbia-Seligman Investments.